Christoph Heuck

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Saad Z. Usmani, Christoph Heuck, Alyson E. Mitchell et al. · Haematologica · 2012 · 389 citations · Full text

Medicine, Hematology, Oncology +17

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

Britta Will, Li Zhou, Thomas O. Vogler et al. · Blood · 2012 · 239 citations · Full text

Medicine, Genetics, Molecular Genetics +14

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

Niels Weinhold, Cody Ashby, Leo Rasche et al. · Blood · 2016 · 213 citations · Full text

Medicine, Cancer Biology, Oncology +14

Induction, binding specificity and function of human ICOS

Katja C. Beier, Andreas Hutloff, Anna‐Maria Dittrich et al. · European Journal of Immunology · 2000 · 177 citations · Full text

Life Sciences, Biochemistry, Immunology +17